Trimel is a specialty pharmaceutical company developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system (“TriVair™”). The Corporation is pursuing the development and application of these technologies for therapeutic categories such as (a) male hypogonadism, (b) female orgasmic disorder, and (c) respiratory disorders, which are significant market opportunities in the United States.
The Corporation’s drug delivery technology platforms are intended to create products that are expected to be safer, more effective, easy to use and more practical than in circumstances where competitive products are on the market. Since the Corporation’s inception, it has focused on the optimization of known high volume pharmaceutical compounds in order to improve their performance and utilization by physicians and patients.